SPOTLIGHT: Worst Pharma Stocks of 2007

When we set out last week to identify the best-performing pharma stocks of 2007, we could resist scrolling to the bottom of the spreadsheet to see what happened on the opposite end of the spectrum. And we figured you'd be equally curious. So here for your perusing pleasure are the 15 companies whose shares lost the most value last year. Special Report

Suggested Articles

Janssen’s BCMA-targeting CAR-T therapy eliminated tumors in 69% of patients with advanced multiple myeloma in a small phase 1 study.

In a study, BMS' CAR-T therapy banished tumors in more than half and shrank tumors in nearly three-quarters of relapsed blood cancer patients.

Novartis unveiled more data showing how its asthma combo QMF149 fared against the standard of care: a combination of the same types of drugs.